Oncology Venture gets option to in-license European rights to IXEMPRA
By Nikita Chaurasia  Date: 2019-04-05

Oncology Venture gets option to in-license European rights to IXEMPRA

Oncology Venture has reportedly gained an exclusive option to in-license the European rights to IXEMPRA® (ixabepilone) from the pharma company R-Pharm U.S., LLC. As per trusted sources, the aforesaid firm acquired global rights to IXEMPRA® from Bristol-Myers Squibb in July 2015 and the drug is permitted in the USA for the treatment of breast cancer.

Oncology Venture will assess ixabepilone along with its drug-specific DRP® companion diagnostic to obtain market approval in Europe.

According to a press release by Oncology Venture, the company has assessed the capacity of its DRP® companion diagnostic to detect which patients will most likely benefit from ixabepilone, depending on previous treatment results and information on tumor gene published by BMS in the scientific literature. The study specifies that patients profiting from Ixabepilone can be recognized through ixabepilone-specific DRP® companion diagnostic. Moreover, the company is certain that it will prevail in its quest to gain EMA approval in order to market ixabepilone across Europe to treat individuals with metastatic breast cancer.

As per the agreement, IXEMPRA® (ixabepilone) will undergo clinical trials in Europe with metastatic breast cancer patients, where the drug will be evaluated by Oncology Venture together with its DRP® companion diagnostic. If the trials unveil convincing results, Oncology Venture will have the option to in-license the commercial rights for IXEMPRA® in the European market. The extended pipeline is not anticipated to surge Oncology Venture’s cost base as the clinical development of ixabepilone will be funded via a special purpose vehicle/joint venture to be open to interested investors while the program will be controlled by Oncology Venture. 

For the record, ixabepilone was initially developed by Bristol-Myers Squibb and was permitted for the treatment of metastatic breast cancer by the US FDA in 2007 but failed to receive approval from the European Medicines Agency for the drug to be marketed in Europe. Currently, the product is marketed by R-Pharm in the USA, as well as in Switzerland, Lichtenstein and some parts of South America, reported sources.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

ClaimBuddy secures undisclosed sum in Titan Capital-led funding round
ClaimBuddy secures undisclosed sum in Titan Capital-led funding round
By Nikita Chaurasia

Indian insurance technology startup ClaimBuddy has reportedly raised an undisclosed amount in a seed funding round which was led by Titan Capital and involved participation from other marquee investor groups including First Cheque as well as LV Angel...

Mercedes-Benz unveils the EQA SUV in a bid to outdo Tesla, Volkswagen
Mercedes-Benz unveils the EQA SUV in a bid to outdo Tesla, Volkswagen
By Nikita Chaurasia

Daimler AG owned German automotive giant, Mercedes-Benz, has reportedly introduced the EQA, a new electric compact SUV to compete with market leader Tesla, Inc. as well as to meet its carbon targets in China and Europe. The Mercedes-Benz EQA, one of...

New York planning on direct purchase of Pfizer’s COVID-19 vaccines
New York planning on direct purchase of Pfizer’s COVID-19 vaccines
By Nikita Chaurasia

In recent developments, Governor of New York, Andrew Cuomo has reportedly issued a letter to the CEO of American drug maker Pfizer Inc., Albert Bourla, requesting for direct purchase of COVID-19 vaccine doses. Although the company is not bound to any...

Mayo Clinic Laboratories forms alliance with American Hospital Dubai
Mayo Clinic Laboratories forms alliance with American Hospital Dubai
By Nikita Chaurasia

In recent developments, Minnesota-based Mayo Clinic Laboratories and American Hospital Dubai are reportedly planning on entering a strategic alliance which is aimed at enhancing advanced laboratory diagnostic services in Dubai. Under the terms of th...

LTI, IBM extend global partnership to spearhead digital transformation
LTI, IBM extend global partnership to spearhead digital transformation
By Nikita Chaurasia

The New York-headquartered IBM Corp., with its global partner Larsen Toubro Infotech, an Indian global IT solutions & services company, are planning to extend their multi-year partnership, in a bid to enable companies to revolutionize the busines...